Supriya Lifescience IPO opened for subscription on 16th December 2021 and it will remain open for bidding till 20th December 2021. Price band of the book built issue has been fixed at ₹265 to ₹274 per equity share. The Active pharmaceutical ingredients (APIs) manufacturer company aims to raise ₹700 crore from its public offer ( ₹200 crore from fresh issue and ₹500 crore through Offer for Sale or OFS). According to market observers, shares of Supriya Lifescience are trading at a premium of ₹275 in grey market today.
By Day 1 of subscription, the public issue has been subscribed 2.33 times whereas the retail portion of the issue has been subscribed 11. times.
Ankur Saraswat, Research Analyst at Trustline Securities said, “Company is one of the leading API manufacturers and largest exporters of HCL and Salbutamol Sulphate in India. It has backward integrated business and diversified products portfolio of 38 APIs with a long list of 1296 customers. The company has global presence in 86 countries. It has advanced manufacturing and research and development capabilities and strong financial performance. So, sentiments are bullish on this niche APIs products based IPO.”
0
0
